Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $878.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 15.09% year-over-year to $878.0 million; the TTM figure through Mar 2026 stood at $878.0 million (down 15.09% YoY), while the FY2025 annual figure was $1.0 billion, up 1.11% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $878.0 million, down from $1.0 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.2 billion in Q3 2024, with the low at $679.0 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $1.0 billion (2025), against an average of $970.8 million.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 181.77% in 2022, then slipped 29.38% in 2025.
• Arcus Biosciences' Total Non-Current Liabilities stood at $1.2 billion in 2022, then fell by 17.84% to $953.0 million in 2023, then grew by 4.2% to $993.0 million in 2024, then increased by 1.11% to $1.0 billion in 2025, then retreated by 12.55% to $878.0 million in 2026.
• Business Quant data shows RCUS's Total Non-Current Liabilities at $878.0 million in Q1 2026, $1.0 billion in Q4 2025, and $822.0 million in Q3 2025.